- Home
- ACB vs NERV Comparison
ACB vs NERV Comparison
Compare ACB & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACB | NERV |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.3M | 210.1M |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACB | NERV |
|---|---|---|
| Price | $2.71 | $4.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | ★ 1.2M | 362.5K |
| Earning Date | 06-17-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.73 | $1.64 |
| 52 Week High | $6.67 | $12.46 |
Technical Indicators
Market Signals| Indicator | ACB | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 31.97 | 50.44 |
| Support Level | N/A | $3.77 |
| Resistance Level | $3.57 | $5.61 |
| Average True Range (ATR) | 0.12 | 0.47 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 1.03 | 49.46 |
Price Performance
Historical ComparisonAbout ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.